I believe you are wrong. It has been states multiple times by Missling that the plan is to have a big pharma partner run the p3 and do p2's themselves on other indications (eg Parkinson, epilipsy)
Changing this plan would be foolish. The company only has 5 employees, how can they run a p3 on their own??